Here, we evaluated the relationship between TP53 alteration and response to immunotherapy among patients in tumor mutational burden (TMB) and immunotherapy database, which included clinical and genomic data from next-generation sequencing of 1662 patients with advanced cancer receiving immunotherapy. Here, TP53 is linked to neoplasm.